MSX-122

Overview

MSX-122 is an orally active partial antagonist of CXCR4 , inhibiting CXCR4/CXCL12 actions, with an IC 50 of ∼10 nM. MSX-122 has anti-inflammatory and anti-metastatic activity.

Application

Products | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-13696
• CAS No.: 897657-95-3
• Molecular Formula: C16H16N6
• Molecular Weight: 292.34
• Purity: 98.16%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 0.4 mg/mL (1.37 mM); Clear solution
• Availability: In-stock

Source

Original product source